Drugging KRAS: current perspectives and state-of-art review

After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncogene in human malignancies. Under normal conditions, KRAS shuttles between the GDP-bound ‘of...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Kaushal, Banna, Giuseppe, Liu, Stephen V., Friedlaender, Alex, Desai, Aakash, Subbiah, Vivek, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597994/
https://www.ncbi.nlm.nih.gov/pubmed/36284306
http://dx.doi.org/10.1186/s13045-022-01375-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597994/
https://www.ncbi.nlm.nih.gov/pubmed/36284306
http://dx.doi.org/10.1186/s13045-022-01375-4

Ejemplares similares